Clinical Trial Update: Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing baricitinib to tofacitinib for refractory axial spondyloarthritis, with status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Spondyloarthritis

Drugs mentioned

• Baricitinib (baricitinib)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Conditions: Spondyloarthritis, Axial | Phase 2 | Status: UNKNOWN